Central Nervous System Pharmaceutical Market in China 2021
- 市场报告
- ID: HL10109C
- 交货时间: 1 工作日
- 标签: Central Nervous System Pharmaceutical
描述
The central nervous system pharmaceutical market in China in terms of revenue is set to grow by US$ 10 亿期间 2021-2027, 以复合年增长率增长 (复合年增长率) 的 4.6% 在预测期内, 据数据和分析公司 StrategyHelix 称.
该报告提供了该时期的最新市场规模数据 2017-2020 并预测到 2027 covering key market aspects like sales value for central nervous system pharmaceutical. The China central nervous system pharmaceutical market is segmented on the basis of type. 按类型, it is categorized into depression, epilepsy, and schizophrenia.
The report has profiled some of the key players of the market such as Biogen Inc., Jiangsu Nhwa Pharmaceutical Co. 有限公司, 约翰逊 & Johnson International Inc., Novartis International AG, Otsuka Pharmaceutical Co. 有限公司, Pfizer Inc., Roche Holding AG.
该报告对于活跃在该行业的公司和组织来说是宝贵的资源. It provides a cohesive picture of the central nervous system pharmaceutical market to help drive informed decision making for industry executives, 政策制定者, 学术的, 和分析师.
报告范围
类型: 沮丧, epilepsy, and schizophrenia
考虑年数: 本报告涵盖期间 2017 到 2027
利益相关者的主要好处
Get a comprehensive picture of the China central nervous system pharmaceutical market
精准定位增长领域和投资趋势
Understand what the future of the central nervous system pharmaceutical market in China looks like
确定竞争格局和机会之窗
目录
1. 市场定义
2. 研究方法论
3. 市场数据 & 外表
3.1 市场价值
3.2 市场价值预测
4. Central Nervous System Pharmaceutical Market by Type
4.1 Depression
4.2 Epilepsy
4.3 Schizophrenia
5. 公司简介
5.1 Biogen Inc.
5.2 Jiangsu Nhwa Pharmaceutical Co., 有限公司.
5.3 约翰逊 & Johnson International, 公司.
5.4 Novartis International AG
5.5 Otsuka Pharmaceutical Co., 有限公司.
5.6 Pfizer, 公司.
5.7 Roche Holding AG
6. 附录
6.1 关于StrategyHelix
6.2 免责声明